Collecting duct carcinoma: Epidemiology, clinical characteristics and survival.

[1]  F. Saad,et al.  Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity , 2022, International Urology and Nephrology.

[2]  Jiaqiao Zhang,et al.  Impact of Treatment Modalities on Prognosis in Patients With Renal Collecting Duct Carcinoma: A Population-Based Study , 2022, Frontiers in Oncology.

[3]  L. Mariani,et al.  Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). , 2022, JAMA oncology.

[4]  C. Porta,et al.  Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma , 2022, Cancer.

[5]  K. Gong,et al.  Collecting duct carcinoma of the kidney: Analysis of 74 cases from multiple centers. , 2022, Urology.

[6]  R. Garje,et al.  Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma , 2022, Frontiers in Oncology.

[7]  Paras H Shah,et al.  Collecting duct carcinoma: A single-institution retrospective study. , 2021, Urologic oncology.

[8]  Wenquan Zhou,et al.  Incidence, Clinical Characteristics, and Survival of Collecting Duct Carcinoma of the Kidney: A Population-Based Study , 2021, Frontiers in Oncology.

[9]  S. Pal,et al.  "Collecting duct carcinoma of the kidney: diagnosis and implications for management". , 2021, Urologic oncology.

[10]  F. Saad,et al.  Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups , 2021, International journal of urology : official journal of the Japanese Urological Association.

[11]  F. Saad,et al.  Renal Cell Carcinoma: Comparison Between Variant Histology and Clear Cell Carcinoma Across all Stages and Treatment Modalities. , 2020, The Journal of urology.

[12]  H. Miyake,et al.  Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney , 2019, International Cancer Conference Journal.

[13]  M. Colecchia,et al.  Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. , 2019, Cancer treatment reviews.

[14]  W. Tu,et al.  Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014 , 2019, Medicine.

[15]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[16]  Y. Nagashima,et al.  Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy , 2018, Medicine.

[17]  F. Zhou,et al.  Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. , 2018, European journal of cancer.

[18]  A. Briganti,et al.  Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. , 2017, European urology focus.

[19]  A. Briganti,et al.  Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era , 2017, International Urology and Nephrology.

[20]  A. Roychoudhury,et al.  Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database. , 2017, Urologic oncology.

[21]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[22]  Y. Allory,et al.  Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Stief,et al.  Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. , 2013, The Journal of urology.

[24]  F. Montorsi,et al.  Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time , 2013, BJU international.

[25]  T. Choueiri,et al.  Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. , 2012, The Lancet. Oncology.

[26]  J. Wright,et al.  Effect of collecting duct histology on renal cell cancer outcome. , 2009, The Journal of urology.

[27]  G. Hédelin,et al.  Conditional relative survival of cancer patients and conditional probability of death , 2009, Cancer.

[28]  S. Culine,et al.  Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.

[29]  N. Rioux-Leclercq,et al.  Collecting duct renal cell carcinoma: a matched analysis of 41 cases. , 2007, European urology.

[30]  R. Motzer,et al.  Targeted therapy for metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Naito,et al.  Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.

[32]  R. Tardanico,et al.  The collecting duct carcinoma of the kidney: a cytogenetical study. , 2003, European urology.